Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kathleen R, Lottenbach"'
Autor:
Kanwaldeep Bajwa, Steven B. Mizel, Ryan C. May, Sharon E. Frey, Kathleen R. Lottenbach, Irene Graham, Robert B. Belshe, Aaron H. Graff, Edwin L. Anderson
Publikováno v:
Vaccine. 35:6759-6765
Introduction Intentional aerosolization of Yersinia pestis may result in pneumonic plague which is highly fatal if not treated early. Methods We conducted a phase 1 randomized, double blind (within each group), placebo controlled, dose escalation tri
Autor:
Thomas P. Pacatte, Azra Blazevic, Aldin Turan, Robert B. Belshe, Stella G. Hoft, Daniel F. Hoft, Michelle C. Mitchell, Kathleen R. Lottenbach, Tamara P. Blevins, Yinyi Yu
Publikováno v:
Clinical and Vaccine Immunology. 24
Both live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) induce protective immunity against influenza. There is evidence that LAIV induces superior protection in children, whereas IIV may induce superior protection in a
Autor:
Margaret B. Rennels, Konstantin Chumakov, Kathleen R. Lottenbach, Robert B. Belshe, Stanley A. Plotkin, Majid Laassri
Publikováno v:
The Journal of Infectious Diseases. 193:1344-1349
Replication of Sabin strains used in oral poliovirus vaccine (OPV) in the intestines of vaccine recipients leads to reversions that increase virus neurovirulence. Previously, a small study reported that prior immunization with inactivated poliovirus
Autor:
Sharon Irby-Moore, Kathleen R. Lottenbach, Donald J. Kennedy, Douglas C. Powers, Dan M. Granoff, Sharon M. Homan, Stephen J. Barenkamp, ChrisAnna M. Mink
Publikováno v:
Journal of the American Geriatrics Society. 52:1883-1887
Objectives: To evaluate the safety and immunogenicity of unconjugated Haemophilus influenzae type b (Hib) polysaccharide (PRP) vaccine and two PRP-protein-conjugated vaccines as a model for the comparison of protein-conjugated versus plain polysaccha
Publikováno v:
Infection and Immunity. 72:3505-3514
Combinatorial cloning and expression library analysis were used to determine the expressed human antibody repertoire specific for the capsular polysaccharide (PS) of Streptococcus pneumoniae serotype 6B. Sequence analysis of 55 6B-specific antibody F
Autor:
Donald C. Reason, Kathleen R. Lottenbach, Jianhui Zhou, Alexander H. Lucas, Stephen J. Barenkamp
Publikováno v:
Infection and Immunity. 70:4083-4091
Combinatorial cloning and expression library analysis were used to isolate human antibody Fab fragments specific for the capsular polysaccharide ofStreptococcus pneumoniaeserotype 23F. Thirty 23F-specific Fabs were isolated from seven vaccinated dono
Autor:
Stephen J. Barenkamp, Douglas C. Powers, Kathleen R. Lottenbach, Edwin L. Anderson, Sharon M. Homan, ChrisAnna M. Mink
Publikováno v:
Infection and Immunity. 67:4935-4938
Immunoglobulin G (IgG) subclass antibody responses to pneumococcal vaccines were determined for human subjects in four age groups. The ratios of IgG1/IgG2 antibody concentrations declined with advancing age for all five of the serotypes tested. Prote
Autor:
Sandra M. Kelly-Aehle, Karen E. Brenneman, Kathleen R. Lottenbach, Sharon E. Frey, rd Roy Curtiss
Publikováno v:
Clinical and vaccine immunology : CVI. 20(9)
Prior to initiating a phase 1 dose escalation trial of the safety and immunogenicity of live, oral, recombinant, attenuated Salmonella enterica serovar Typhi vaccine strains in human subjects, the suitability of conventional blood culture procedures
Publikováno v:
Journal of Infectious Diseases. 173:1014-1018
Healthy adults > or = 50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (beta197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 microgram each of capsular oligosaccharides
Autor:
Getahun Abate, Isaac G. Sakala, Steven M. Truscott, Kathryn M. Edwards, Edwin L. Anderson, Robert B. Belshe, Irene Graham, Shewangizaw Worku, Charles T. Spencer, David I. Bernstein, Daniel F. Hoft, Frances K. Newman, Michael A. Gerber, Elizabeth Babusis, C. Buddy Creech, Kathleen R. Lottenbach
Publikováno v:
The Journal of infectious diseases. 204(6)
Background. Two doses of either trivalent live attenuated or inactivated influenza vaccines (LAIV and TIV, respectively) are approved for young children ($24 months old for LAIV and $6 months old for TIV) and induce protective antibody responses. How